Evolus Inc. shares fell 31% to $3.65 following a non-binding initial decision against the company in a U.S. International Trade Commission dispute concerning Botox rival Jeuveau. Botox maker Allergan, which is now a unit of AbbVie Inc., and Medy-Tox Inc. filed a complaint in January 2019 against Evolus and Daewoong Pharmaceutical Co.
